Cybin has dosed the last patient in Part B of its three-part CYB004-E Phase I clinical trial of CYB004 in healthy volunteers.
CYB004 is being evaluated as a potential therapy for the treatment of generalised anxiety disorder with or without major depressive disorder.
Go deeper with GlobalData
Discover B2B Marketing That Performs
Combine business intelligence and editorial excellence to reach engaged professionals across 36 leading media platforms.
The study is evaluating the pharmacokinetics, pharmacodynamics, and safety of escalating doses of intravenous N,N-dimethyltryptamine (IV DMT) molecule CYB004 in healthy subjects.
Being conducted at the Centre for Human Drug Research in the Netherlands, the CYB004-E study is said to be one of the largest Phase I DMT trials till date.
Cybin CEO Doug Drysdale said: “We are pleased with the continued progress we are making with our CYB004 programme and excited to reach our next key milestone of first-in-human dosing with our novel CYB004 molecule.
“Through Part C of the trial, we will have the ability to evaluate CYB004 in humans earlier than expected and potentially demonstrate the advantages of deuteration on pharmacokinetic/pharmacodynamic parameters, enabling a less invasive and more convenient dose form that may eliminate the need for specialised and costly clinical centres for dosing.”
US Tariffs are shifting - will you react or anticipate?
Don’t let policy changes catch you off guard. Stay proactive with real-time data and expert analysis.
By GlobalDataPart C of the study intends to evaluate IV bolus along with infusion regimens of CYB004 in a crossover manner.
For further clinical trials, dose selection and formulation will be decided based on the results of Part B and C studies.
Topline data from the completed Phase I study is expected in the third quarter of this year.
